Effect of switching glatiramer acetate formulation from 20 mg daily to 40 mg three times weekly on immune function in multiple sclerosis

Kouichi Ito, Naoko Ito, Sudhir K Yadav, Shradha Suresh, Yong Lin and Suhayl Dhib-Jalbut

Abstract

Background: Many RRMS patients who had been treated for over 20 years with GA 20 mg/ml daily (GA20) switched to 40 mg/ml three times-a-week (GA40) to reduce injection-related adverse events. Although GA40 is as effective as GA20 in reducing annualized relapse rate and MRI activity, it remains unknown how switching to GA40 from GA20 affects the development of pathogenic and regulatory immune cells.

Objective: To investigate the difference in immunological parameters in response to GA20 and GA40 treatments.

Methods: We analyzed five pro-inflammatory cytokines (IL-1β, IL-23, IL-12, IL-18, TNF-α), and three anti-inflammatory/regulatory cytokines (IL-10, IL-13, and IL-27) in serum. In addition, we analyzed six cytokines (IFN-γ, IL-17A, GM-CSF, IL-10, IL-6, and IL-27) in cultured PBMC supernatants. The development of Th1, Th17, Foxp3 Tregs, M1-like, and M2-like macrophages were examined by flow cytometry. Samples were analyzed before and 12 months post switching to GA40 or GA20.

Results: Pro- and anti-inflammatory cytokines were comparable between the GA40 and GA20 groups. Development of Th1, Th17, M1-like macrophages, M2-like macrophages, and Foxp3 Tregs was also comparable between the two groups.

Conclusions: The immunological parameters measured in RRMS patients treated with GA40 three times weekly are largely comparable to those given daily GA20 treatment.

Keywords: Multiple sclerosis, glatiramer acetate, cytokines, regulatory T-cells

Date received: 18 April 2021; Revised received: 22 June 2021; accepted: 24 June 2021
Indeed, the incidence of injection site reaction (ISRs) in RRMS patients treated with GA40 was reduced by 20-50% compared to those treated with GA20. However, it is unknown whether switching from GA20 to GA40 treatment affects the immunological parameters involved in the response to GA. In this study, we studied the difference in pro-inflammatory and regulatory immune responses generated by GA20 and GA40 treatments and regulators.

Materials and methods

Subjects

Enrolled subjects in this study were participants in TEVA Pharmaceuticals clinical trial entitled “Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone™”. This study is registered at clinicaltrials.gov (NCT00203020). Participants who were originally randomized to the placebo group in the 01-9001 and/or the 01-9001E studies received glatiramer acetate 20 milligrams (mg) subcutaneous (SC) injection daily at the start of this study. After 18 July 2014 participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg three times weekly (TIW).

Participants were required to have the following study-specific baseline characteristics: a diagnosis of RRMS as defined by Poser et al 1983, at least 2 clearly identified relapses and remissions in the 2-year period prior to study entry, ambulatory with a Kurtzke EDSS score of 0 to 5.0 inclusive, and a stable neurologic state for at least 30 days prior to study entry. Patients provided written informed consent prior to undergoing study-related procedures. The study for blood collection was approved by study sites Institutional Review Boards and blood samples were transported overnight to our Laboratory in Piscataway, NJ. The immunological study using the collected blood was approved by Rutgers Institutional Review Board (Pro20140000929). The patient demographic information is shown in Table 1.

Analysis of cytokine production

Human PBMCs were isolated from whole blood by using lymphocyte separation medium (Thermo Fisher Scientific, Waltham, MA). The freshly isolated PBMCs were cultured at 4 × 10^6/ml with GA (Teva Pharmaceutical Industries Ltd., Israel) at 50 μg/ml, LPS (InvivoGen, San Diego, CA) at 5 μg/ml, or CD3/CD28 mAbs (Biolegend, San Diego, CA) at 2 μg/ml for 3 days, and cytokine production was examined by ELISA (Biolegend, San Diego, CA). The remaining cells were frozen and stored in liquid nitrogen. The serum was isolated from the blood by using BD Vacutainer (Becton Dickinson, Franklin Lakes, NJ), and the serum concentration of cytokines was examined by LEGENDplex™ (Biolegend, San Diego, CA).

Analysis of pathogenic and regulatory immune cells

The frozen PBMCs were thawed and cultured with CD3/CD28 mAbs in the presence of brefeldin A (10 μg/mL) and then stained with pooled CD4, IFN-γ, IL-17A, GM-CSF, and TNF-α mAbs, and concentrations of CD4^+IFN-γ^+, CD4^+IL-17A^+, CD4^+GM-CSF^+, CD4^+TNF-α^+ were examined by flow cytometry (Supplementary Figure 1(a)). M1-like macrophages (CD14^+HLA-DR^+) were examined by staining with CD14 and HLA-DR mAbs (Biolegend, San Diego, CA). M2-like macrophages (CD14^+CD206^+) were examined by staining with CD14 and CD206 mAbs (Biolegend, San Diego, CA). Naive and memory Foxp3 Tregs were examined by staining with CD3, CD4, CD45RA, and Foxp3 mAbs (Biolegend, San Diego, CA).

Statistical analysis

The Shapiro-Wilk test was used to test the normality assumptions for the differences and the ratios of immunological parameters between baseline and 12 months post-baseline as well as the normality assumptions of the log transformed data. For the differences between baseline and 12 months post-baseline, Student’s paired t-test or Signed Rank sum test were used depending on the normality assumptions holds or not. For the comparisons on the ratios of 12-month post-baseline and baseline between GA40 and GA20, since the normality assumptions do not hold, log-transformations were used first. If normality assumption held for the transformed data, either equal or unequal variance two-sample t-test was used depending on the homogeneity of variances between the two samples. If the normality assumption did not hold, Wilcoxon rank sum test was used for the comparison of transformed data between GA40 and GA20. All P-values ≤ 0.05 were considered statistically significant.

Results

Comparison of serum cytokine levels between GA20 and GA40

Blood samples were collected from RRMS patients before switching from GA20 to GA40 (baseline) and
12 months post switching (n = 28). Follow-up blood samples at 12 months were also obtained from RRMS patients who continued to take GA20 (n = 16). The demographics of the participants are shown in Table 1. We analyzed the pro-inflammatory cytokines; IL-1β, IL-23, IL-12, IL-18, IFN-γ, and IL-17A, and the anti-inflammatory/regulatory cytokines; IL-10, IL-13, and IL-27. A bead-based immunoassay was used to measure serum cytokine levels; and then, the change in the ratio for cytokine concentrations at 12 months of treatment relative to baseline was examined. We observed a decrease in this ratio for IL-1β, IL-23, IL-12, IL-18, IFN-γ, IL-17A, and TNF-α in RRMS patients treated with GA40 compared to those given GA20; however, the differences were not statistically significant except for serum TNF-α levels (Figure 1(b) and (d)). The change of ratio for TNF-α serum levels was significantly lower in GA40-treated patients compared to GA20-treated patients (Figure 1(d)).

### Comparison of ex-vivo PBMC IL-10 production between GA20 and GA40

IL-10 production by PBMCs in response to GA is thought to contribute to the therapeutic mechanism of the drug. Therefore, PBMCs isolated from MS patients treated with GA20 or GA40 were cultured with GA; and the production of IL-10, IL-17A, IFN-γ, and GM-CSF was measured by ELISA. We observed an increasing trend in IL-10 production 12 months post switching in both treatment groups (Figure 2(a)). However, the difference in the ratio for IL-10 production at 12 months relative to baseline between GA40 and GA20 groups was not significant (Figure 2(b)). We also examined the production of IL-10 by PBMCs in response to CD3/CD28 stimulation and LPS stimulation (Figures 3 and 4). Again, the change in ratio for IL-10 production in these conditions was not significantly different between the GA40 and GA20 groups (Figures 3(b) and 4(b)). Collectively, these data suggest that IL-10 production by PBMCs is comparable between GA20 and GA40 therapy.

### Discussion

GA is an immunomodulatory drug for patients with RRMS. Adverse events result from the high

---

**Table 1. Patient demographic information.**

| Factor                        | GA20 (n = 16) | GA40 (n = 28) |
|-------------------------------|--------------|--------------|
| Age (mean yr ± SD)            | 57±6         | 59±6         |
| Women: Men (women %)          | 11:5 (69%)   | 18:10 (64%)  |
| Duration of MS (mean yr ± SD) | 27±3         | 32±5         |
| Duration of GA medication (mean yr ± SD) | 21±1         | 22±1         |
| EDSS                          | 2.8±1.6      | 3.4±2.5      |

---

Comparison of the development of pathogenic and regulatory immune cells

The development of Th1, Th17, and ThGM-CSF cells are associated with disease activity in RRMS. Therefore, we examined the development of Th1 (CD4⁺IFN-γ⁺ or CD4⁺TNF-α⁺), Th17 (CD4⁺IL-17⁺), and ThGM-CSF (CD4⁺GMCSF⁺) cells in RRMS patients treated with GA40 or GA20 at baseline and at 12 months post switching. The ratio of the percentage cell phenotype at 12 months relative to baseline was calculated for each subject. As shown in Figure 5, we did not observe a significant difference in the change of ratio for the development of Th1 (IFN-γ), Th1 (TNF-α), Th17, or ThGM-CSF cells between the two groups. Development of Foxp3 Tregs is associated with suppression of disease activity and progression. The naïve and memory Foxp3 Tregs possess suppressive activity and GA-treatment can increase the development of naïve Foxp3 Tregs. Therefore, we examined the development of naïve Foxp3 Tregs in RRMS patients given GA20 or GA40. As shown in Figure 6(a), we did not observe a significant difference in the development of naïve Foxp3 Tregs between GA20 and GA40 groups (Figure 6(a)). The development of memory Foxp3 Tregs was also not different between the two groups (Figure 6(a)). Next, we examined the development of M1-like (CD14⁺HLA-DRhi) and M2-like (CD14⁺CD206⁺) macrophages. M1-like macrophages play a pathogenic role in disease progression, while M2-like macrophages play a protective role in neuroinflammation. As shown in Figure 6(b), there was no significant difference in the development of M1-like and M2-like macrophages between the GA20 and GA40 groups. These results suggest that development of pathogenic and regulatory immune cells are largely comparable between GA20 and GA40 treatments.
Figure 1. Cytokine concentration in serum. (a and c) Serum cytokine levels in RRMS patients treated with GA40 or GA20. Baseline (B.L.): before switching from GA20 to GA40. 12M: 12 months after switching to GA40. GA40; n=28, GA20; n=17. (b and d) Change in serum cytokine levels between B.L. and 12M. The cytokine ratio represents cytokine level at 12 M divided by that at B.L. for each subject *P<0.05.

Figure 2. Cytokine production by PBMCs in response to GA. (a) PBMCs were cultured with GA at 50 μg/ml for 3 days, and production of cytokines was measured by ELISA. (b) Change in cytokine production between B.L. and 12M. Cytokine production at 12M is divided by that at B.L. *P<0.05 **P<0.01.
frequency of subcutaneous injections associated with a daily dose of GA at 20 mg/ml; hence, a higher dose of 40 mg/ml of GA administered 3 times a week was examined for therapeutic efficacy, lessening adverse events related to injection frequency, and potentially improved compliance. The reduced frequency of subcutaneous injections of GA40 led to a reduction of adverse events, but with sustained efficacy on clinical relapses and MRI activity. One concern shared by physicians and patients alike is whether the reduced GA-injection frequency from daily to three time weekly in the long-run affects the immune responses associated with the therapeutic mechanism of the drug; a question we intended to address in this study.

Serum cytokine levels are one of the immunological parameters associated with disease onset, relapse, and response to treatment in MS. The serum levels of IL-1β, IL-23, IL-12, IL-18, IL-13, IFN-γ, IL-17A, IL-27, and TNF-α are elevated in RRMS patients compared to healthy donors, while serum IL-10 levels are lower in RRMS. Importantly, serum levels of IL-23, IL-12, IL-18, IL-13, IFN-γ,
IL-17A, IL-27, and TNF-α are elevated upon relapse.20–23 Interestingly, GA treatment reduces serum levels of IL-1β, IL-12, IL-18, IFN-γ, and IL-17A.24–27 In contrast, serum levels of IL-10, IL-13, IL-27, and TNF-α are elevated with GA treatment.26,28,29 Compared to those under GA20 therapy, a downward trend was observed for the serum levels of tested cytokines, except IL-13, in RRMS patients treated with GA40 (Figure 1(b) and (d)). This indicates that a reduction in the frequency of GA administration is not associated with a reduction in the impact of GA40 on pro-inflammatory cytokines.

The induction of IL-10 is one of the presumed therapeutic mechanisms of action for GA. IL-10 is...
produced by T cells, B cells, and myeloid cells; and GA treatment can promote the production of IL-10 from these leukocytes. Therefore, we examined the production of IL-10 from PBMCs isolated from RRMS patients under GA40 and GA20 treatments by cultivation with GA (Figure 2), CD3/CD28 mAb (Figure 3), and LPS (Figure 4). We did not observe a significant difference in the change in ratio for IL-10 production at 12 months relative to baseline between GA40 and GA20 treatments. Since IL-27 can induce the production of IL-10, and is a biomarker for clinical response to GA, production of IL-27 in response to LPS was also examined. The change in ratio for IL-27 production was also not different between the GA40 and GA20 groups (Figure 4). These data suggest that the effect on IL-10 and IL-27-mediated immunomodulation is comparable between the GA40 and GA20 groups.

GA treatment can induce the development of type 2 antigen presenting cells (APCs) that promote the development of Th2 cells, and consequently, the production of anti-inflammatory cytokines. M2-like macrophages are one of the type 2 APCs that play a protective role in neuroinflammation. M1-like macrophages are pathogenic myeloid cells highly involved in neuroinflammation. GA treatment can promote M2-like macrophages and suppress the development of M1-like macrophages. Therefore, we examined the development of M1-like and M2-like macrophages. The change of ratio (12 months relative to baseline) for both M1-like and M2-like macrophages was comparable between GA40 and GA20 groups (Figure 6(b)). Type 2 APCs can also promote the development of Foxp3 Tregs that play a pivotal role in suppression of disease onset and relapse. While the frequency of naïve and memory Foxp3 Tregs is low in RRMS patients compared to healthy donors, GA treatment can promote the development of naïve types of Foxp3 Tregs. As shown in Figure 6(a), the population of memory Foxp3 Tregs is higher than that of naïve Foxp3 Tregs, and the change of ratio for naïve and memory Foxp3 Tregs was comparable between GA40 and GA20 groups. We also examined the development of Th1, Th17, and ThGM-CSF cells. Similarly, we did not observe a difference in change in ratio for these T cells between the two treatment groups (Figure 5).

Collectively, our results indicate that the immunologic effects of GA40 and GA20 treatment regimens are largely comparable as expected and that less frequent GA injections are not inferior to daily dosing in generating the desired immunologic effects. These results are also consistent with the mechanism of action of GA and its clinical efficacy studies.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S. D-J received grant support from Teva Pharmaceuticals and Biogen. K. I received financial support for research activities from Teva Pharmaceuticals and Biogen.

Acknowledgements
The Ruth Dunietz Kushner and Michael Jay Serwitz endowed Chair in Multiple Sclerosis to Dr. Dhib-Jalbut.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Teva pharmaceuticals grant: 01-9004 Immune Studies.

ORCID iD
Kouichi Ito https://orcid.org/0000-0002-0424-2125

Reference
1. Dhib-Jalbut S. Glatiramer acetate (copaxone) therapy for multiple sclerosis. Pharmacol Ther 2003; 98: 245–255.
2. Prod’homme T and Zamvil SS. The evolving mechanisms of action of glatiramer acetate. Cold Spring Harb Perspect Med 2019; 9: a029249.
3. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group. Neurology 1995; 45: 1268–1276.
4. Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105: 967–976.
5. Miller A, Shapiro S, Gershtein R, et al. Treatment of multiple sclerosis with copolymer-1 (copaxone): implicating mechanisms of Th1 to Th2/Th3 immunodomination. J Neuroimmunol 1998; 92: 113–121.
6. Comi G, Filippi M and Wolinsky JS, et al.; European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging – measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290–297.
and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50: 701–708.

8. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of cop 1 in exacerbating–remitting multiple sclerosis. N Engl J Med 1987; 317: 408–414.

9. Comi G, Martinelli V, Rodegher M, et al.; PreCISe Study Group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503–1511.

10. Comi G, Cohen JA, Arnold DL, et al.; FORTE Study Group. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol 2011; 69: 75–82.

11. Zivadinov R, Bergsland N, Hagemeier J, et al. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal DTI study. J Neurol Sci 2018; 387: 152–156.

12. Khan O, Rieckmann P, Boyko A, et al. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the glatiramer acetate low-frequency administration open-label extension study. Mult Scler 2017; 23: 818–829.

13. Khan O, Rieckmann P, Boyko A, et al.; GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013; 73: 705–713.

14. Wolinsky JS, Borresen TE, Dietrich DW, et al.; GLACIER Study Group. GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2015; 4: 370–376.

15. Vieira PL, Heystek HC, Wormmeester J, et al. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 2003; 170: 4483–4488.

16. Valmori D, Merlo A, Souleimanian NE, et al. A peripheral circulating compartment of natural naive CD4 tregs. J Clin Invest 2005; 115: 1953–1962.

17. Haas J, Korpal M, Balint B, et al. Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis. J Neuroimmunol 2009; 216: 113–117.

18. Martinez FO and Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014; 6: 13–13.

19. Nally FK, De Santi C and McCoy CE. Nanomodulation of macrophages in multiple sclerosis. Cells 2019; 8: 543.

20. Carrieri PB, Provitera V, De Rosa T, et al. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol Immuno toxicol 1998; 20: 373–382.

21. Hollifield RD, Harbiges LS, Pham-Dinh D, et al. Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity 2003; 36: 133–141.

22. Nicoletti F, Di Marco R, Mangano K, et al. Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology 2001; 57: 342–344.

23. Cala CM, Moseley CE, Steele C, et al. T cell cytokine signatures: biomarkers in pediatric multiple sclerosis. J Neuroimmunol 2016; 297: 1–8.

24. Gran B, Tranquill LR, Chen M, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000; 55: 1704–1714.

25. Burger D, Molnarfi N, Weber MS, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA 2009; 106: 4355–4359.

26. Trenova AG, Slavov GS, Manova MG, et al. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis. Scand J Clin Lab Invest 2017; 77: 283–288.

27. Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004; 172: 7144–7153.

28. Wiesemann E, Klatt J, Wenzel C, et al. Correlation of serum IL-13 and IL-5 levels with clinical response to glatiramer acetate therapy. J Neuroimmunol 2001; 133: 454–460.

29. Mindur JE, Valenzuela RM, Yadav SK, et al. IL-27: a pro-inflammatory and anti-inflammatory cytokine. Clin Exp Immunol 2003; 133: 454–460.

30. Ireland SJ, Guzman AA, O’Brien DE, et al. The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis. J Immunol 2004; 177: 1268–1275.

31. Venken K, Hellings N, Broekmans T, et al. Natural naive CD4+CD25+CD127low regulatory T cell (treg) development and function are disturbed in multiple sclerosis patients: recovery of memory treg homeostasis during disease progression. J Immunol 2008; 180: 6411–6420.